Kampanjeplan Zentalis Pharmaceuticals, Inc.
Avansert tidsplan
Enkel graf
Om selskapet
Zentalis Pharmaceuticals, Inc., биофармацевтическая компания, работающая на клинической стадии, разрабатывает маломолекулярные терапевтические препараты для лечения различных видов рака в Соединенных Штатах. Его ведущим кандидатом в продукте является ZN-c5, пероральный селективный деструктор рецепторов эстрогена, который проходит фазу I клинических испытаний для лечения запущенного или метастатического рака молочной железы.
Flere detaljerP/BV | 6.39 |
---|---|
EV/EBITDA | 1.75 |
EBITDA | -0.0467 |
Цена ао | 3.98 |
Сайт | http://zentalis.com |
Число акций ао | 0.06541 млрд |
ISIN | US98943L1070 |
Выручка | 1.4E-5 |
Валюта | usd |
IPO date | 2020-04-03 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Prisendring per dag: | +1.7% (2.94) |
---|---|
Prisendring per uke: | -11.28% (3.37) |
Prisendring per måned: | -5.08% (3.15) |
Prisendring over 3 måneder: | -24.87% (3.98) |
Prisendring over seks måneder: | -77.47% (13.27) |
Prisendring per år: | -84.05% (18.75) |
Prisendring over 3 år: | -96.01% (74.9) |
Prisendring siden begynnelsen av året: | -72.37% (10.82) |
|
Undervurdering
|
Effektivitet
|
|||||||||||||||||||||||||||||||||||||
Utbytte
|
Plikt
|
Vekstimpuls
|
Institusjoner | Volum | Dele, % |
---|---|---|
Matrix Capital Management | 13959973 | 19.67 |
Eventide Asset Management LLC | 11559975 | 16.29 |
FMR, LLC | 10336971 | 14.57 |
Vanguard Group Inc | 5350458 | 7.54 |
Blackrock Inc. | 4684975 | 6.6 |
State Street Corporation | 4417056 | 6.22 |
Citadel Advisors Llc | 3681782 | 5.19 |
Price (T.Rowe) Associates Inc | 2904065 | 4.09 |
Capital International Investors | 2819664 | 3.97 |
T. Rowe Price Investment Management, Inc. | 2341783 | 3.3 |
ETF | Dele, % | Lønnsomhet for året, % | Utbytte, % |
---|---|---|---|
Avantis U.S Small Cap Equity ETF | 0.00858 | 27.774101036841 | 1.68271 |
Avantis U.S. Equity ETF | 0.00015 | 30.365392144069 | 1.59151 |
Virtus LifeSci Biotech Clinical Trials ETF | 0.35112 | 63.040315712071 | 0.33 |
JPMorgan BetaBuilders U.S. Small Cap Equity Fund | 0.01504 | 24.74842126706 | 1.59225 |
ProShares Ultra Nasdaq Biotechnology | 0.01963 | 51.697637072723 | 0.85651 |
Range Cancer Therapeutics ETF | 0.40311 | 47.24446537918 | 0.11955 |
Dimensional US Core Equity Market ETF | 0.00002 | 30.983243755928 | 1.40618 |
Vanguard ESG U.S. Stock ETF | 0 | 32.395678092399 | 1.26927 |
ProShares Hedge Replication ETF | 0.00146 | 5.9237999659878 | 1.47892 |
Invesco Nasdaq Biotechnology ETF | 0.02985 | 29.399255715045 | 0.8565 |
iShares Morningstar Small-Cap ETF | 0.00506 | 30.095066471445 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.00454 | 33.628071953382 | 0.72598 |
iShares Morningstar Small Cap Value ETF | 0.00516 | 26.701717953559 | 2.50476 |
iShares Russell 3000 ETF | 0.0004 | 31.230028873917 | 1.43482 |
iShares Morningstar Small-Cap ETF | 0.00506 | 391.25300933451 | 1.60498 |
iShares Morningstar Small-Cap Growth ETF | 0.00454 | 682.83677107207 | 0.72598 |
iShares Morningstar Small-Cap Value ETF | 0.00516 | 226.82308420057 | 2.50476 |
Direxion Daily S&P Biotech Bull 3x Shares | 0.05874 | 4067.9190751445 | 0.25924 |
Invesco FTSE RAFI US 1500 Small-Mid ETF | 0.00501 | 32.025164769323 | 1.75869 |
Schwab U.S. Small-Cap ETF | 0.00561 | -34.641922436355 | 1.51433 |
Schwab U.S. Broad Market ETF | 0.0004 | -56.193181818182 | 1.43354 |
ProShares UltraPro Russell2000 | 0.00521 | 89.821266282945 | 1.47873 |
Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
Vanguard Russell 2000 ETF | 0.01 | 32.773459189339 | 1.48801 |
Principal Healthcare Innovators ETF | 0.02751 | 618.4964157054 | 0.8416 |
Future Tech ETF | 0.02751 | 426.33969118983 | 0.8416 |
Veileder | Stillingstittel | Betaling | Fødselsår |
---|---|---|---|
Dr. Kimberly Lynn Blackwell M.D. | CEO & Director | 1.12M | 1969 (55 år) |
Mr. Cameron S. Gallagher M.B.A. | Co-Founder, President, Interim CFO, Interim Treasurer & Director | 767.69k | 1970 (54 år) |
Ms. Andrea Paul J.D. | Chief Legal Officer & Corporate Secretary | 668.2k | 1981 (43 år) |
Dr. Mark Lackner Ph.D. | Chief Scientific Officer | N/A | 1968 (56 år) |
Ms. Kimberly Freeman | Chief Strategy Officer | N/A | |
Dr. Kyle Rasbach Ph.D., Pharm.D. | Chief Business Officer | N/A | 1980 (44 år) |
Mr. Vincent Vultaggio | VP of Finance & Interim Principal Accounting Officer | 1983 (41 år) |
Adresse: United States, New York, NY , 530 Seventh Avenue - åpne i Google maps, åpne Yandex-kart
Nettsted: http://zentalis.com
Nettsted: http://zentalis.com